DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for dyshidrosis — screening already-approved drugs against its 26-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDyshidrosis maps to a 26-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dyshidrosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
retinol binding protein 1 (RBP1) — RBP1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4-methylphenyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8GD2 · 1.13 Å · ligand N-methyl-1-{3-[1-(4-methylphenyl)cyclopentyl]-1,2,4-oxadiazol-5-yl}-N-[(thiophen-2-yl)methyl]methanamine (Z5H). Experimental structure, not a prediction.
What the evidence adds up to
Dyshidrosis is a chronic dermatitis of the hands and feet that can cause physical discomfort, psychological distress, and occupational impairment. A 2006 review notes the condition is often difficult to manage. A 2023 review states dyshidrotic dermatitis accounts for up to 80% of people of all ages and genders, describes its etiology as idiopathic, and says some sources link it to a history of atopy or a combination of environmental and genetic factors. The same review reports that hyperhidrosis is found in almost a third of sufferers and can be associated with atopic dermatitis, contact dermatitis, or reactions to systemic drugs including anti-retrovirals, intravenous immunoglobulin, and mycophenolate-mofetil.
Histological evidence from 1986 shows that the dyshidrotic vesicle is an intraepidermal, spongiotic lesion and that the intraepidermal part of the eccrine sweat duct is not altered even by spongiosis. The authors concluded the term "dyshidrosis" is a misnomer and that the condition is spongiotic dermatitis modified by the distinctive characteristics of palmar and plantar skin. A 2023 review acknowledges that while some sources state vesicles are caused by sweat gland dysfunction, histological examination of the sweat gland ducts is not abnormal.
A 1999 study of 30 patients with syringomyelia and Chiari malformation found that 26.7% had segmental hypohidrosis, 33.3% had segmental hyperhidrosis, and 40.0% had normohidrosis. Karnofsky functional status was significantly higher for the hyperhidrosis and normohidrosis groups than for the hypohidrosis group (p=0.0012). Duration from onset of syringomyelia to current dyshidrosis was significantly longer in the hypohidrosis group than in the hyperhidrosis group (p=0.0027). The authors concluded that in early syringomyelia, focal hyperhidrosis may be a hallmark of a relatively intact spinal cord.
Treatment options mentioned in the 2006 review are not specified beyond being difficult. The 2023 review states corticosteroids and emollients are the main choice, and that retinoids and immunomodulators may be considered according to clinical condition. It describes dyshidrotic dermatitis as a chronic and recurrent disease requiring periodic control and patient education to avoid precipitating factors. What remains missing are controlled trials comparing these treatments, any quantitative response or survival data, and a clear patient stratification that separates idiopathic cases from those secondary to systemic disease or drug reactions.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Dermatitis · 2006 · 99 citations
Dyshidrosis: Epidemiology, Clinical Characteristics, and Therapy
AbstractDyshidrosis is a common chronic dermatitis of the hands and feet that may cause significant physical discomfort, psychological distress, and occupational impairment. Topics reviewed in this article include epidemiology, clinical findings, quality of life, and therapeutic considerations. Dyshidrosis is often difficult to manage; therefore, extra attention is given in this review article to current treatment options.
American Journal of Dermatopathology · 1986 · 47 citations
Are Acrosyringia Involved in the Pathogenesis of "Dyshidrosis"?
AbstractInvestigations of dyshidrotic eruptions of various causes were done by conventional and electron microscopy. In all cases, the histological patterns were identical. The dyshidrotic vesicle is an intraepidermal, spongiotic lesion. The intraepidermal part of the eccrine sweat duct (acrosyringium) is not altered even by spongiosis. As the acrosyringium does not take part in formation of a dyshidrotic vesicle, the term "dyshidrosis" has to be regarded as a misnomer. Dyshidrosis is nothing but spongiotic dermatitis modified by the distinctive characteristics of palmar and plantar skin.
Journal of Neurology Neurosurgery & Psychiatry · 1999 · 38 citations · open access
Focal (segmental) dyshidrosis in syringomyelia
AbstractThe features or mechanisms of dyshidrosis have not been sufficiently clarified. Neither has the difference between hyperhidrosis and hypohidrosis. To clarify the features and mechanisms of dyshidrosis (hyperhidrosis and hypohidrosis) in syringomyelia, the clinical features focusing on hidrosis of 30 patients with syringomyelia and Chiari malformation located from a syringomyelia database were prospectively analysed. The patients were classified into three groups: eight patients (26.7%) had segmental hypohidrosis, 10 (33. 3%) had segmental hyperhidrosis, and 12 (40.0%) had normohidrosis. We found that the Karnofsky functional status for the hyperhydrosis and normohidrosis groups were significantly higher than for the hypohidrosis group (p=0.0012), with no significant differences between the hyperhidrosis and normohidrosis groups. The duration from the onset of syringomyelia to the current dyshidrosis was significantly longer in the hypohidrosis group than in the hyperhidrosis group (p=0.0027). A significant correlation was identified between the duration from the onset of syringomyelia to the time at study and the performance score (r=-0.599, p=0.0003). The results substantiate previous hypotheses that in its early stage syringomyelia causes segmental hyperactivity of the sympathetic preganglionic neurons, and hyperactivity of these gradually subsides as tissue damage progresses. Focal hyperhidrosis may be regarded as a hallmark of a relatively intact spinal cord, as well as normohidrosis.
Usada Nusantara Jurnal Kesehatan Tradisional · 2023 · 0 citations · open access
Dermatitis Dishidrotik
AbstractDyshidrotic dermatitis is a form of hand and foot dermatitis characterized by fluid accumulation in the form of vesicles or bullae. Dyshidrotic dermatitis is the most common form of skin disease, accounting for up to 80% of people of all ages and genders. The etiology of dyshidrotic dermatitis is idiopathic, but some sources link the etiology with a history of atopy. There are also sources that state that the etiology of dyshidrotic dermatitis is a combination of various factors, such as environmental and genetic factors. Pathogenesis of dyshidrotic dermatitis, states that dyshidrotic dermatitis vesicles are caused by sweat gland dysfunction. However, it turns out that the histological examination of the sweat gland ducts is not abnormal. However, hyperhidrosis (excessive sweating) is found in almost a third of dyshidrosis dermatitis sufferers and can also be associated with atopic dermatitis, contact dermatitis, or reactions to systemic drugs. (anti-retrovirals, intravenous immunoglobulin, mycophenolate-mofetil immunosuppressant). Treatment can be in the form of corticosteroids and emollients are the main choice in management of dyshidrotic dermatitis. Other therapies such as retinoids and Immumomodulators may also be considered according to clinical conditions patient dyshidrotic dermatitis, is a chronic and recurrent disease, so the patient must be controlled periodically and receive education to avoid precipitating facto.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
